Description
Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others.
This new study from Kalorama discusses the emerging vaccine technologies and the competitive and clinical landscape in which they will emerge. Extensive interviewing of industry participants has revealed the revenues of the existing competitors that we belive have never been published, and market models based on epidemiology, likely clinical acceptance, and regulatory events and validated with this existing revenue information predicts market size, growth, and share for emerging products in the United States and the world through 2008.
Table of Contents
Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: The Emerging Cancer Vaccine Market
- History and Growth of the Cancer Treatment Market
- Cancer Vaccine Technology
- Industry Structure
- Demographics and Statistics
Chapter Three: Current Cancer Vaccine Market
- Overview
- Description of Cancers with Available Vaccines
- Bladder Cancer
- Colorectal Cancer
- Melanoma
- Description of Products
- TheraCys (ImmuCyst)
- M-Vax
- Melacine
- OncoVax
- Pacis
- Market Size and Growth
- Competitive Analysis
Chapter Four: Emerging Cancer Vaccine Potential
- Overview
- Description of Cancers with Potential Vaccines
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- Kidney
- Leukemia
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Prostate Cancer
- Sarcoma
- Cancer Vaccine Pipeline
- Market and Product Launch Forecasts
- Potential Competitors and Analysis, 2008
Chapter Five: Issues and Trends Affecting the Cancer Vaccine Market
- Introduction
- Early Detection and Screening
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- New application for Tobacco Plant
Chapter Six: The Emerging Cancer Vaccine Market: Total Market Size and Forecast
- Overview
- Total Market Size and Forecast
- Competitor Analysis
- Market Analysis
Chapter Seven: Corporate Profiles
- AVAX Technologies, Inc.
- Aventis Pasteur, Inc.
- Corixa Corporation
- Intracel Holdings Corporation
- Shire Biochem, Inc.
Chapter Eight: Emerging Vaccine Corporate Profiles
- Advaxis, Inc.
- Aphton Corporation
- Antigenics, Inc.
- AVI BioPharma, Inc.
- Berlex, Inc.
- Biomira, Inc.
- Biovest International, Inc.
- CancerVax Corporation
- Cell Genesys, Inc.
- CYTOGEN Corporation
- Dendreon Corporation
- Epimmune, Inc.
- Favrille, Inc.
- GeneMax Corporation
- Genitope Corporation
- Genzyme Molecular Oncology
- Geron Corporation
- GlaxoSmithKline plc
- IDM, S.A.
- ImClone Systems, Inc.
- Immune Response Corporation, The
- Large Scale Biology Corporation
- Medarex, Inc.
- MedImmune, Inc.
- Merck & Company, Inc.
- Northwest Biotherapeutics, Inc.
- Oxford BioMedica plc
- Progenics Pharmaceuticals, Inc.
- Therion Biologics Corporation
- Titan Pharmaceuticals, Inc.
- Transgene S.A.
- United Biomedical, Inc.
- Vical, Inc.
- Wyeth
- YM BioSciences, Inc.
Appendix A: Company Names and Addresses
Appendix B: Regulatory Authorities and Organizations
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Current and Emerging Market – Cancer Vaccines, 2001-2008
- Figure 1-1: Current and Emerging Market – Cancer Vaccines, 2001-2008
Chapter Two: The Emerging Cancer Vaccine Market
- Table 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Common Type of Cancer, 2003 and 2020
- Table 2-2: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
- Figure 2-2: Estimated and Projected World Cancer Mortality by Common Type of Cancer, 2003 and 2020
- Table 2-3: World Population by Selected Geographical Region, 2003-2050
- Figure 2-3: World Population by Selected Geographical Region, 2003-2050
- Table 2-4: Estimated World Population by Age and Geographical Region, 2003
- Figure 2-4: Estimated World Population by Age and Geographical Region, 2003
- Table 2-5: Life Expectancy at Birth by Selected Countries, 2000
- Table 2-6: United States Life Expectancy at Birth, 1990-2000, and Projections, 2005-2010
- Figure 2-5: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2000
- Figure 2-6: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2000
Chapter Three: Current Cancer Vaccine Market
- Table 3-1: Malignant Conditions Of The Skin
- Table 3-2: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers with Potential Vaccines
- Figure 3-1: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers with Potential Vaccines
- Table 3-3: Current Cancer Vaccines Market, 2001-2008
- Figure 3-2: Current Cancer Vaccines Market, 2001-2008
- Table 3-4: Leading Suppliers Shares by Market Revenues, Estimated 2003
- Figure 3-3: Leading Suppliers Market Share, Estimated 2003
Chapter Four: Emerging Cancer Vaccine Potential
- Table 4-1: Types of Leukemia
- Table 4-2: Types of Primary Lung Cancer
- Table 4-3: Classification of Non-Hodgkin’s Lymphomas
- Table 4-4: Malignant Conditions of The Skin
- Table 4-5: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers with Potential Vaccines
- Figure 4-1: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers with Potential Vaccines
- Table 4-6: Cancer Vaccines in the Pipeline
- Table 4-7: Cancer Vaccines: Emerging Cancer Vaccines Market, 2004-2008
- Figure 4-2 Cancer Vaccines: Emerging Cancer Vaccines Market, 2004-2008
- Table 4-8: Cancer Vaccines: Emerging Cancer Vaccines Market by Type, 2004-2008
- Table 4-9: Cancer Vaccines: Emerging Cancer Vaccines Market by Type – Revenues and Percent Distribution, 2004-2008
- Figure 4-3: Cancer Vaccines: Emerging Cancer Vaccines Market by Type – Revenues and Percent Distribution, 2004-2008
- Figure 4-4: Cancer Vaccines: Emerging Cancer Vaccines Market by Percent Distribution, 2004-2008
- Figure 4-5: Cancer Vaccines: Emerging Cancer Vaccines Market by Percent andProduct Type, 2008
- Table 4-10: Leading Suppliers Shares by Market Revenues, Based on Emerging Vaccines – Projected 2008
- Figure 4-6: Leading Suppliers Shares by Market Revenues, Based on Emerging Vaccines – Projected 2008
- Table 4-11: Competitors by Cancer Vaccine Type, Based on Emerging Vaccines – Projected 2008
- Figure 4-7: Competitors by Cancer Vaccine Type, Based on Emerging Vaccines – Projected 2008
Chapter Five: Issues and Trends Affecting the Cancer Vaccine Market
- Table 5-1: Cancer Detection Tests
Chapter Six: The Emerging Cancer Vaccine Market: Total Market Size and Forecast
- Table 6-1: Cancer Vaccines, 2001-2008
- Figure 6-1: Cancer Vaccines, 2001-2008
- Table 6-2: Cancer Vaccines by Current and Emerging Markets, 2001-2008
- Table 6-3: Cancer Vaccines by Current and Emerging Market Revenues and Percent Distribution, 2001-2008
- Figure 6-2: Cancer Vaccines by Current and Emerging Market Revenues and Percent Distribution, 2001-2008
- Figure 6-3: Cancer Vaccines Current and Emerging Markets by Percent Distribution, 2001-2008
- Figure 6-4: Current and Emerging Cancer Vaccines Market by Percent, 2008
- Table 6-4: Cancer Vaccines: Current and Emerging Suppliers and Developers of Cancer Vaccines by Cancer Type
- Figure 6-5: Cancer Vaccines: Competitors by Cancer Vaccine Type and Number of Products Available or in Development
- Figure 6-6: Cancer Vaccines: Cancer Vaccines Available or in Development by Cancer Type, 2003
- Figure 6-7:Cancer Vaccines: Competitors by Cancer Vaccine Availability and/or Number of Vaccines in Development
- Figure 6-8: Cancer Vaccines: Competitors by Cancer Vaccine Availability and/or Number of Vaccines in Development
